Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of the Effect of the Association of Proton Pump Inhibitor (PPIs) With Non-Steriodal Anti-Inflamatories (NSAIDs) in Work Leave Time.

This study has been completed.
Ibermutuamur M.A.T.E.P.S
Information provided by:
AstraZeneca Identifier:
First received: July 14, 2008
Last updated: September 12, 2008
Last verified: July 2008
Retrospective cohort study to evaluate the effect of the association of PPIs with NSAIDs in work leave time.

Sprain of Ankle

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Evaluation of the Effect of the Association of Proton Pump Inhibitor (PPIs) With Non-Steriodal Anti-Inflamatories (NSAIDs) in Work Leave Time.

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Total work leave time [ Time Frame: Jan 2007 to Dec 2007 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • GI complications [ Time Frame: Jan 2007 to Dec 2007 ] [ Designated as safety issue: No ]
  • Direct medical costs [ Time Frame: Jan 2007 to Dec 2007 ] [ Designated as safety issue: No ]

Enrollment: 6356
Study Start Date: April 2008
Study Completion Date: August 2008
Patients with sprain of ankle treated with NSAID


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Data base of patients with work leave due to a sprain of ankle

Inclusion Criteria:

  • Work leave due to a sprain of ankle

Exclusion Criteria:

  • (none)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00717119

Research Site
Madrid, Spain
Sponsors and Collaborators
Ibermutuamur M.A.T.E.P.S
Study Director: Javier N Rivero, MSc Epidemiology Unit. AstraZeneca
  More Information

Responsible Party: Mónica Tafalla/MD, PhD, AstraZeneca Pharmaceuticals Identifier: NCT00717119     History of Changes
Other Study ID Numbers: NIS-GES-DUM-2008/3 
Study First Received: July 14, 2008
Last Updated: September 12, 2008
Health Authority: Spain: Ethics Committee

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Anti-Inflammatory Agents, Non-Steroidal
Proton Pump Inhibitors
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on January 14, 2017